Information Provided By: 
Fly News Breaks for May 21, 2015
IPCI
May 21, 2015 | 11:47 EDT
Brean Capital said it believes Intellipharmaceutics has already demonstrated bioequivalence for Rexista in its recent FDA submission and estimates that being able to skip Phase 3 testing would save the company 18-24 months of time and at least $20M in development costs. The firm has a Buy rating and $8 price target on Intellipharmaceutics.
News For IPCI From the Last 2 Days
There are no results for your query IPCI
